Nearly 200 years after the introduction of the stethoscope, the accuracy of a pocket ultrasound device that enables a physician to “look” at a patient’s heart during routine physical exams has been validated for the first time in peer-reviewed research led by Scripps Translational Science Institute (STSI) and Scripps Health.
Roughly the size of a smart phone, the Vscan™ pocket ultrasound used for point of care assessment of heart health could significantly reduce costs from traditional echocardiograms and improve the quality of care. Research was published in the July 5 issue of the Annals of Internal Medicine.
To view Multimedia News Release, go to http://www.multivu.com/mnr/50963-vscan-pocket-ultrasound-echocardiogram-stethoscope
Today, Solta Medical, Inc. (Nasdaq: SLTM), the pioneer in fractional resurfacing and non-invasive skin tightening and a global market leader in aesthetic treatments, announced the arrival of its groundbreaking Liposonix technology in the United States and Canada. Using advanced high-intensity focused ultrasound (HIFU) technology, Liposonix is a non-surgical permanent fat reduction procedure that has been clinically shown to slim down the waistline by one pant or dress size without surgery or downtime. It is indicated for non-invasive waist circumference reduction for use on both the abdomen and love handles.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54037-solta-liposonix-custom-contouring-waistline-fat-reduction
EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, announced today that new 10 year data from an international registry-based multi-center study shows 83 percent of patients had no biopsy evidence of disease after treatment with Ablatherm® HIFU, supporting the technology as a standard primary treatment for localized prostate cancer. Study results were presented at the American Urological Association (AUA) 2011 Annual Meeting, Washington, D.C.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/edap/49862/
InSightec Ltd, the leader in magnetic resonance imaging (MRI)-guided Focused Ultrasound therapy, announced that the U.S. Food and Drug Administration (FDA) has approved ExAblate® MRI-guided focused ultrasound as a therapy to treat pain from bone metastases in patients who do not respond or cannot undergo radiation treatment for their pain. This is the second FDA approval for ExAblate, which has been used widely since it was approved in 2004 as a non-invasive, outpatient, therapy for uterine fibroids.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56632-insightec-fda-approves-exablate
After only 16 weeks of existence, foetuses hear and respond to music as long as it is emitted from their mother’s vagina. Foetuses respond to this stimulus by opening their mouths and pulling their tongues out as far as possible, making vocalisation movements – prior to the acquisition of language.
This is the main conclusion of the study conducted by the team of Institut Marquès, which boasts the collaboration of Alberto Prats, Professor of Anatomy and Human Embryology of the Faculty of Medicine of the University of Barcelona.
The study, entitled “Foetal facial expression in response to intravaginal music emission”, is published this week in the journal Ultrasound of the British Medical Ultrasound Society (BMUS).
According to Dr. Marisa López-Teijón, the Head of Assisted Reproduction at Institut Marquès and the principal researcher and author of the clinical study: “We have discovered that the formula for foetuses to hear like us is to emit music from the mother’s vagina. They barely hear the sound that reaches them through their mother’s abdomen: the soft tissues of the abdomen and the inside of the mother’s body absorb the soundwaves”.
To view the multimedia release go to:
http://www.multivu.com/players/English/7647351-how-foetuses-hear-musical-stimuli/
